- Home
- BIIB
BIIB
Biogen Inc.
as 02-21-2025 3:32pm EST
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
| Founded: | 1978 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 20.5B | IPO Year: | 1991 |
| Target Price: | $220.50 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 27 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 11.18 | EPS Growth: | 40.28 |
| 52 Week Low/High: | $128.51 - $238.00 | Next Earning Date: | 02-12-2025 |
| Revenue: | $9,675,900,000 | Revenue Growth: | -1.62% |
| Revenue Growth (this year): | -0.51% | Revenue Growth (next year): | 1.57% |
Latest Biogen Inc. News
BIIB Breaking Stock News: Dive into BIIB Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
3 days ago
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
Simply Wall St.
3 days ago
We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative
Benzinga
4 days ago
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
MT Newswires
4 days ago
Bernstein Adjusts Price Target on Biogen to $159 From $160, Keeps Market Perform Rating
MT Newswires
4 days ago
Piper Sandler Adjusts Price Target on Biogen to $135 From $138, Keeps Neutral Rating
MT Newswires
4 days ago
Biogen, Stoke Partner on Dravet Syndrome Investigational Drug Zorevunersen
Business Wire
4 days ago
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
BioPharma Dive
4 days ago
Biogen buys rights to Stoke’s rare epilepsy drug
Compare BIIB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIIB Biogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.